This review will explore antioxidative, Nrf2-involving treatments targeting different risk factors of diabetic dyslipidemia (e.g., VLDL, sdLDL, hepatic lipolysis-stimulated lipoprotein receptor (LSR) impairment), how each of the risk factors causes atherosclerosis, and how the treatments can therefore be used to treat atherosclerosis in patients with DM. This evidence concerns the gene NFE2L2 and atherosclerosis.